Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intra-Cellular Ther (NQ: ITCI )

74.54 +2.17 (+3.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Intra-Cellular Ther

< Previous 1 2 3 4 5 Next >
Analyst Ratings for Intra-Cellular Therapies
Via Benzinga
Airbnb To Rally Around 59%? Here Are 10 Other Analyst Forecasts For Wednesday
Keybanc raised the price target for Intuit Inc. (NASDAQ: INTU) from $450 to $475. Keybanc analyst Josh Beck maintained an Overweight rating. Intuit shares fell 1.8% to close at $419.33 on Tuesday. 
Via Benzinga
Why Alibaba Shares Are Trading Higher By Over 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Intra-Cellular Stock Surges As Antipsychotic Shows Benefit In Depression Patients With Mixed Features
Via Benzinga
Analyst Ratings for Intra-Cellular Therapies
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
Earnings Outlook For Intra-Cellular Therapies
Via Benzinga
Looking Into Intra-Cellular Therapies's Return On Capital Employed
Via Benzinga
Why Intra-Cellular Therapies Climbed Tuesday
The company's depression drug, Caplyta (lumateperone), did well in a phase 3 trial against two types of depression. 
Via The Motley Fool
Intra-Cellular's Big Depression Drug Market Just Got Bigger — And Shares Catapulted
The company believes it may have the answer for patients with "mixed features." 
Via Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Recap: Intra-Cellular Therapies Q3 Earnings
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Intra-Cellular Therapies's Earnings: A Preview
Intra-Cellular Therapies (NASDAQ:ITCI) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Looking Into Intra-Cellular Therapies's Return On Capital Employed
Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $55.58 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 20.08%, resulting in a loss of $86.60... 
Via Benzinga
Where Intra-Cellular Therapies Stands With Analysts
  Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings: 
Via Benzinga
Robust Uptake Of Antipsychotic Drug Boosts Intra-Cellular's Q1 Earnings
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022
Upgrades 
Via Benzinga
Illumina, Poshmark, Olo And Some Other Big Losers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Intra-Cellular Therapies: Q2 Earnings Insights
  Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
Upgrades 
Via Benzinga
Analyst Ratings for Intra-Cellular Therapies
Over the past 3 months, 4 analysts have published their opinion on Intra-Cellular Therapies (NASDAQ:ITCI) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
Upgrades 
Via Benzinga
Looking Into Intra-Cellular Therapies's Return On Capital Employed
According to Benzinga Pro data, during Q1, Intra-Cellular Therapies (NASDAQ:ITCI) posted sales of $35.00 million. Earnings were up 15.88%, but Intra-Cellular Therapies still reported an overall loss of... 
Via Benzinga
Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97. 
Via Investor's Business Daily
103 Biggest Movers From Yesterday
Gainers 
Via Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Recap: Intra-Cellular Therapies Q1 Earnings
Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 22, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.